N-Hydroxyamide Derivatives for Selective MMP Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current matrix metalloproteinase inhibitors exhibit dose-limiting side effects such as muscoskeletal syndromes, highlighting the need for inhibitors with a well-defined specificity profile, particularly for MMP-1 and MMP-14, to effectively treat autoimmune disorders, inflammatory diseases, and other conditions without adverse effects.
Innovation Solution
Development of N-hydroxyamide derivatives that modulate, specifically inhibit the activity of matrix metalloproteinases, particularly gelatinases and elastases, to treat autoimmune disorders, inflammatory diseases, and other conditions, including the use of pharmaceutical compositions and methods of synthesis for these derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing matrix metalloproteinase inhibitors are used to treat autoimmune disorders and inflammatory diseases, then the therapeutic effect is achieved, but dose-limiting side effects such as muscoskeletal syndromes occur
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (N-hydroxyamide derivatives with defined R1-R6 groups) that confer selective affinity for particular MMP subtypes (especially MMP-1 and MMP-14) over other MMPs. This structural specificity allows the inhibitor to target the harmful MMP activity causing muscoskeletal side effects while preserving beneficial MMP functions in other tissues, thereby resolving the contradiction between therapeutic effect and side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecule (substituents R1-R6, chiral centers, conjugation patterns) to optimize the balance between potency and selectivity. By adjusting these molecular parameters, the invention achieves high inhibition of pathogenic MMPs while minimizing off-target effects, thus eliminating the dose-limiting side effects while maintaining therapeutic efficacy.
2Adaptability or versatility
If broad-spectrum MMP inhibitors are used, then multiple disease indications are covered, but specificity and selectivity are reduced leading to more side effects
Solution Approach 1:
The patent applies segmentation by dividing the broad MMP family into specific subtypes (collagenases MMP-1, MMP-13; gelatinases MMP-2, MMP-9; stromelysins MMP-3, MMP-10; elastases MMP-12, MMP-14) and designing inhibitors with differentiated affinities for each segment. The N-hydroxyamide scaffold allows independent optimization of binding interactions with specific MMP regions, enabling selective inhibition of pathogenic subsets while sparing beneficial ones, thus achieving both versatility and precision.
Solution Approach 2:
The patent implements local quality through structure-activity relationship (SAR) analysis that identifies specific binding pockets and catalytic sites within different MMP subtypes. The N-hydroxyamide derivatives are designed with functional groups positioned to interact selectively with conserved residues in target MMPs, creating local molecular recognition features that confer subtype specificity while maintaining overall therapeutic coverage across multiple disease indications.
Data Source
AI summary
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.